GlycArt News
Most Popular GlycArt Story
Roche oncology chief sees big impact of sugar tech
Three years after plunking down $180 million to buy GlycArt, Roche says the sugar-related technology it acquired in the deal is demonstrating striking effectiveness enhancing experimental cancer... Read more...
Latest Headlines
- October 3, 2008
- June 25, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
